Business Wire

AGCO Agriculture Foundation Donates to UK's Biggest Charity Fighting Hunger and Tackling Food Waste

28.11.2022 22:52:00 EET | Business Wire | Press release

Share

The AGCO Agriculture Foundation (AAF), a private foundation with the vision to prevent and relieve hunger through sustainable agricultural development, today announced a USD 300,000 grant to FareShare to ensure surplus food reaches vulnerable communities in the United Kingdom while tackling food waste.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221128005695/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

AAF grant to FareShare to secure 475 tonnes of surplus food. (Photo: Business Wire)

The two-year partnership is expected to help FareShare secure 475 tonnes of surplus food and redistribute more than one million meals. The project will assist in growing the award-winning Surplus with Purpose Fund, which covers the cost for farmers to harvest and divert food that would have otherwise been wasted.

The Intergovernmental Panel on Climate Change estimates that food waste contributes between 8 and 10 percent of global greenhouse gas emissions, so tackling food waste is a pressing issue. The funding will also directly help agricultural businesses by reducing the environmental effect of food waste through interventions to harvest fresh surplus products such as fruit and vegetables. Over the next 24 months, for every tonne of surplus food FareShare and AAF redistribute through this project, approximately 1.6 tonnes of embedded CO2 could be saved, and another 3.8 tonnes could be prevented from harmful alternative disposal.

"As a foundation, our support of the FareShare surplus food project comes at a crucial time and aligns with AAF's vision to prevent and relieve hunger. We hope to support the food needs of these vulnerable households while combating climate change at both ends of the food chain by tackling food waste," said Roger Batkin, Board Chair, AGCO Agriculture Foundation.

The AAF-funded surplus food project contributes to four of The United Nations' 17 Sustainable Development Goals: Zero Hunger, Good Health and Well-being, Climate Action and Responsible Consumption and Production. The project will supply food for thousands of vulnerable people, tackle food waste to address climate change impact, improve overall well-being through access to good nutrition and provide a scalable solution to rescue food.

"We should never be wasting good food, especially not amid a cost-of-living crisis. Millions of people are struggling with the rise in food prices, fuel and household bills. We've seen the impact of demand for food across our network skyrocketing. FareShare is grateful to the AAF for extending their funding to the UK at this crucial time. This partnership will help us further our reach and make a meaningful difference in getting surplus food from farms to people's plates," said Lindsay Boswell, Chief Executive Officer of FareShare.

About AGCO

AGCO (NYSE:AGCO) is a global leader in the design, manufacture and distribution of agricultural machinery and precision ag technology. AGCO delivers customer value through its differentiated brand portfolio including core brands like Challenger®, Fendt®, GSI®, Massey Ferguson®, Precision Planting® and Valtra®. Powered by Fuse® smart farming solutions, AGCO's full line of equipment and services help farmers sustainably feed our world. Founded in 1990 and headquartered in Duluth, Georgia, USA, AGCO had net sales of approximately $11.1 billion in 2021. For more information, visit www.AGCOcorp.com. For company news, information and events, please follow us on Twitter: @AGCOCorp. For financial news on Twitter, please follow the hashtag #AGCOIR.

About the AGCO Agriculture Foundation (AAF)

The AGCO Agriculture Foundation (AAF), initiated by AGCO Corporation (NYSE: AGCO) in 2018, is a private foundation with the vision to prevent and relieve hunger. The foundation initiates impactful programs that support food security, foster sustainable agricultural development and build needed agricultural infrastructure in marginalized farming communities. AAF is domiciled in Vaduz, Liechtenstein and operations are managed from Duluth, Georgia, USA. For more information, please visit https://www.agcofoundation.org/

About FareShare

FareShare is the UK's biggest charity fighting hunger and tackling food waste since 1994. The charity organization is born out of the belief that no good food should go to waste, especially when people are going hungry. FareShare redistributes its surplus food through a network of nearly 9,500 charities and community organizations.

For more information, visit our website: https://fareshare.org.uk/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Aryn Drawdy, Corporate Communications Director
aryn.drawdy@agcocorp.com

Holly Howells, FareShare
Holly.Howells@fareshare.org.uk

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye